Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Call for equitable EU access to cardiac treatments:

This article was originally published in Clinica

Executive Summary

EU governments need to step up efforts to ensure that patients suffering from heart conditions have equitable access to reliable innovative treatments. That was the appeal being made by the Health First Europe alliance of patients, healthcare workers, academics, experts and industry on World Heart Day 2004 (September 26). Investment in new and innovative technologies is necessary to stay ahead of the disease, the HFE says. Cardiac resynchronisation therapy, for example, reduces mortality, improves quality of life and reduces the number of hospitalisation days and the financial costs to healthcare systems. Each year, over 600,000 cases of heart failure are diagnosed, with some 330,000 new cases annually in the UK, France, Germany, Italy and Spain alone.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT059709

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel